Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
PROGENICS PHARMACEUTICALS INC (PGNX)
|
Add to portfolio |
|
|
|
| Price: |
$4.35
| | Metrics |
| OS: |
86.6
|
M
| |
-218
|
% ROE
|
| Market cap: |
$377
|
M
| |
-188
|
% ROIC
|
|
Net debt:
|
$7.88
|
M
| |
|
|
|
EV:
|
$385
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($61.5)
|
M
| |
|
|
|
EBIT
|
($64.1)
|
M
| |
|
|
| EPS |
($0.78)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 |
| Revenues | 35.0 | 15.6 | 11.7 | 69.4 | 8.7 | 44.4 | 7.9 | 14.0 |
| Revenue growth | 124.0% | 33.5% | -83.2% | 700.2% | -80.4% | 464.4% | -44.0% | -83.4% |
| Cost of goods sold | 3.2 | 82.0 | 2.6 | -60.9 | 0.0 | -61.3 | -51.0 | 1.2 |
| Gross profit | 31.8 | -66.4 | 9.1 | 130.4 | 8.7 | 105.6 | 58.9 | 12.9 |
| Gross margin | 90.9% | -424.8% | 77.8% | 187.8% | 100.0% | 238.0% | 749.2% | 91.7% |
| Selling, general and administrative | 47.8 | 29.4 | 24.9 | 23.4 | | | | |
| Research and development | 49.2 | 35.1 | 42.6 | 37.6 | 28.2 | 28.6 | 34.6 | 31.3 |
| General and administrative | | | | | 18.2 | 15.5 | 15.5 | 15.2 |
| EBITA | -64.1 | -48.5 | -55.6 | 8.7 | -39.3 | 6.0 | -42.1 | -35.5 |
| EBITA margin | -183.3% | -310.2% | -475.3% | 12.6% | -453.0% | 13.6% | -535.0% | -252.6% |
| Amortization of intangibles | 1.1 | 0.5 | 0.2 | 0.2 | | | | |
| EBIT | -65.2 | -49.0 | -55.8 | 8.5 | -39.3 | 6.0 | -42.1 | -35.5 |
| EBIT margin | -186.5% | -313.4% | -477.0% | 12.2% | -453.0% | 13.6% | -535.0% | -252.6% |
| Pre-tax income | -68.5 | -69.3 | -62.7 | 12.6 | -39.3 | 3.4 | -42.9 | -35.4 |
| Income taxes | 0.0 | -1.6 | -11.7 | 1.8 | -0.1 | -1.0 | -0.4 | 0.0 |
| Tax rate | | 2.4% | 18.6% | 14.7% | 0.3% | | 0.8% | 0.0% |
| Net income | -68.6 | -67.7 | -51.0 | 10.8 | -39.1 | 4.4 | -42.6 | -35.4 |
| Net margin | -195.9% | -433.1% | -436.1% | 15.6% | -450.8% | 9.9% | -541.5% | -252.2% |
| |
| Diluted EPS | ($0.80) | ($0.87) | ($0.73) | $0.15 | ($0.56) | $0.06 | ($0.76) | ($1.02) |
| Shares outstanding (diluted) | 85.6 | 77.9 | 70.3 | 70.2 | 69.7 | 68.2 | 55.8 | 34.8 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|